Xuelin Huang
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Mediation analysis is a pivotal tool for elucidating the indirect effect of an environmental factor or treatment on disease through potentially high-dimensional omics data, such as gene expression profiles. However, traditional mediation analysis methods tailored for binary outcomes often rely on the rare disease assumption in logistic regression and provide inadequate measures of total mediation effect when multiple mediators have effects in different directions. In this paper, we develop a MEdiation analysis framework in LOgistic regression for high-Dimensional mediators and a binarY outcome (MELODY). It leverages a second-moment-based measure analogous to the R 2 for linear models to quantify the total mediation effect. We also develop a variable selection procedure for high-dimensional data to reduce bias introduced by non-mediators. Our comprehensive simulations demonstrate the superior performance of MELODY in scenarios with non-rare disease binary outcomes and high-dimensional mediators. We apply MELODY to the Framingham Heart Study of over 5000 individuals to analyze the mediation effects of metabolomics and transcriptomics data on the pathways from sex to incident coronary heart disease.
Year:
2025
With the advancement of medical treatments, many historically incurable diseases have become curable. An accurate estimation of the cure rates is of great interest. When there are no clear biomarker indicators for cure, the estimation of cure rate is intertwined with and influenced by the specification of hazard functions for uncured patients. Consequently, the commonly used proportional hazards (PH) assumption, when violated, may lead to biased cure rate estimation. Meanwhile, longitudinal biomarker measurements for individual patients are usually available. To accommodate non-PH functions and incorporate individual longitudinal biomarker trajectories, we propose a new joint model for cure, survival, and longitudinal data, with hazard ratios between different covariate subgroups flexibly varying over time. The proposed joint model has individual random effects shared between its longitudinal and cure-survival submodels. The regression parameters are estimated by maximization of the non-parametric likelihood via the Monte Carlo expectation-maximization algorithm. The standard error estimation applies a jackknife resampling method. In simulation studies, we consider crossing and non-crossing survival curves, and the proposed model provides unbiased estimates for the cure rates. Our proposed joint cure model is illustrated via a study of chronic myeloid leukemia.
Year:
2025
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
Year:
2024
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Year:
2024
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Year:
2024
Supplementary Figure 1 shows (A) spider plots of Log 2 of individual tumor volumes, (B) growth curves representing average Log 2 tumor volumes, (C) spider plots of Log 2 of proportional changes in tumor volume, and (D) growth curves showing Log2 proportional changes in tumor volume of the data shown in Figures 1 and 2.
Year:
2024
Summary In the era of big data, machine learning techniques are widely applied to every area in biomedical research including survival analysis. It is well recognized that censoring, which is a common missing issue in survival time data, hampers the direct usage of these machine learning techniques. Here, we present CondiS, a web toolkit with graphical user interface to help impute the survival times for censored observations and predict the survival times for future enrolled patients. CondiS imputes a censored survival time based on its distribution conditional on its observed part. When covariates are available, CondiS-X incorporates this information to further increase the imputation accuracy. Users can also upload data of newly enrolled patients and predict their survival times. As the first web-app tool with an imputation function for censored lifetime data, CondiS web can facilitate conducting survival analysis with machine learning approaches. Availability and implementation CondiS is an open-source application implemented with Shiny in R, available free at: https://biostatistics.mdanderson.org/shinyapps/CondiS/. Supplementary information Supplementary data are available at Bioinformatics online.
Year:
2022
Collaborators (21)
Lawrence Rubinstein
Statistician
National Cancer Institute
Jose G. Trevino
Virginia Commonwealth University
Michael A. Davies
-
Min Jin Ha
Assistant Professor
The University of Texas MD Anderson Cancer Center
Lisa McShane
Associate Director, Division of Cancer Treatment & Diagnosis
National Cancer Institute
Ruosha Li
Professor
The University of Texas Health Science Center at Houston
Jeffrey Chuang
Jackson Laboratory
Alana Welm
Chair
Huntsman Cancer Institute
Nicholas Mitsiades
Professor
University of California, Davis
Bryan Welm
Associate Professor
Huntsman Cancer Institute
Meenhard Herlyn
Professor, Director
The Wistar Institute
Jing Wang
Professor
The University of Texas MD Anderson Cancer Center
Ryan C. Fields
University of Rochester
Luis G Carvajal‐Carmona
Professor
University of California, Davis
Funda Meric-Bernstam
The University of Texas MD Anderson Cancer Center
Salma Kaochar
Assistant Professor
Baylor College of Medicine
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
J. Chuck Harrell
Virginia Commonwealth University
Michael Lewis
Baylor College of Medicine
Soner Koc
GlaxoSmithKline Research and Development
Peng Wei
Professor
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.